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        Autoimmunity is the predominant eff  ec-
tor mechanism of T1D, but not its pri-
mary cause. Why the immune system 
becomes activated and attacks  cells in 
certain individuals is not clear. The causes 
of T1D include both intrinsic and ex-
trinsic factors involving the patients’ gen-
otype, epigenotype, and environment. 
  That autoimmune processes drive 
the massive      cell destruction in certain 
forms of diabetes mellitus has been rec-
ognized for more than 30 yr. During the 
1920s and 1960s, several pathologists re-
ported   “  infl  ammation involving the is-
lands of Langerhans  ”   (insulitis) in juvenile 
T1D. In the mid-1970s, autoantibodies 
against pancreatic islet cell antigens were 
identifi  ed in the sera of patients who had 
recently developed T1D (  1  ), and a pre-
disposing role for certain   HLA   geno-
types was established (  2, 3  ). However, 
despite the approximately 18,000 papers 
on T1D etiology that have followed 
these initial discoveries, the precise causes 
and initiating events that drive this dis-
ease in humans remain unclear. 
  In siblings of young T1D patients, 
autoantibodies against unidentifi  ed islet 
cell antigens were found to predict fail-
ure of insulin secretion and hyperglyce-
mia (  4  ). The major      cell antigens 
recognized by autoantibodies were later 
identifi  ed as insulin, glutamic acid de-
carboxylase (GAD), and protein tyro-
sine phosphatase receptor type N (IA-2 
proteins), and these antigens are now 
used for routine serological testing. 
Young children whose B cells produce 
signifi  cant amounts of these autoanti-
bodies will usually, but not always, ex-
perience a subacute decline of      cell 
function and will soon become hyper-
glycemic ( 5  ). And although specifi  c sub-
sets of T lymphocytes are known to be 
key players in T1D, their precise place 
in the natural history of the disease re-
mains to be elucidated. 
  On page   2975   of this issue, Orešic ˇ 
et al. present intriguing data that may 
provide hints about the etiology of this 
disease. The authors report characteristic 
changes in specifi  c  serum  metabolites 
that precede the appearance of GAD- 
and insulin-specifi  c autoantibodies and 
other metabolic changes that predict 
which children will eventually develop 
T1D (  6  ). 
  Metabolic prelude to T1D 
  Orešic ˇ et al. compared serum metab-
olite profi   les between children who 
eventually developed T1D and those 
who remained healthy and autoanti-
body-free (  6  ). This analysis uncovered 
characteristic metabolic changes only in 
the children who later developed T1D, 
including reduced serum succinate, 
phoshatidylcholine, and phospholipids, 
as well as decreased ketoleucine and el-
evated glutamic acid. 
  This sort of metabolomic approach 
to T1D natural history may be a pio-
neering example of new environmental 
data-driven approaches. It is not yet 
clear how higher levels of circulating 
glutamate, succinate, ketoleucine, or 
branched-chain amino acid might nor-
mally interfere with T1D initiation. It 
is also diffi   cult to envision how these 
changes might have occurred. They 
could refl  ect an asymp    tomatic infection 
of the liver or muscle, a dietary event, 
or a metabolic disturbance in response 
to environmental cues. 
  Glutamate, which was elevated in 
children who went on to develop dia-
betes, is present in food, but presumably 
not in quantities capable of in  creasing 
serum levels to the extent reported 
(    32-fold above normal). Elevated se-
rum glutamate in conjunction with di-
minished     -ketoglutarate could also 
result from increased muscle catabolism 
or impairment of the liver glutamate-
dehydrogenase pathway and ureagene-
sis (  7  ). It is also important to keep in 
mind that plasma glutamine and gluta-
mate comprise only a small fraction of 
total intracellular glutamate pools and 
do not necessarily refl  ect the kinetics of 
whole-body fl  uxes  (  8  ). Humans who 
consume 10 g or more of monosodium 
glutamate have double the normal plasma 
glutamate levels and higher insulin con-
centrations (  9  ). Although the total glu-
tamate intake in Europe ranges from 
5 to 12 g/d (  10  ), glutamate is also endo-
genously synthesized with a turnover 
A new study reveals distinctive metabolic changes that precede the develop-
ment of type 1 diabetes (T1D), tossing a stone into the quiet waters of T1D 
immunology and genetics. The causes of these metabolic changes and their 
relationship to autoimmunity and  cell destruction are not yet known, but 
the identifi  cation of a metabolic phenotype linked to susceptibility to type I 
diabetes may help pave the way to a new era of investigation of T1D 
causality.
  P.B. is at Department of Pediatric Endocrinology and 
U561 INSERM, Saint Vincent de Paul Hospital, Paris V 
Ren  é   Descartes University, 75014 Paris, France. 
  A.-J.V. is at Unit  é   de Sant  é   Publique and U707 
INSERM, Saint Antoine Hospital, Paris VI Pierre et 
Marie Curie University, 75012 Paris, France. 
 CORRESPONDENCE   
 P.B.:  bougneres@paris5.inserm.fr  
  Causes of early-onset type 1 diabetes: toward data-driven 
environmental approaches 
    Pierre     Bougn  è  res   and   Alain-Jacques     Valleron   
© 2008 Bougnères and Valleron  This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites 
license for the fi  rst six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).2954  TYPE 1 DIABETES ENVIROMENTOME   | Bougn  è  res and Valleron 
ments, and through travel. Thus, it is 
unlikely that the hygiene hypothesis can 
solely explain the rapid rise of T1D 
cases in very young children. However, 
we may be able to fi  nd traces of relevant 
microbiological encounters in oropha-
ryngeal or gut microbiomes by testing 
serological markers, or by quantifying 
the burden of childhood infection epi-
demics (  20  ). 
  A shift toward hypothesis-
generating research 
  Marcel Proust wrote that   “  discovery 
needs new eyes more than new lands.  ”   
T1D research certainly needs both. The 
new lands might include factors that af-
fect a child  ’  s environment from peri-
conception to disease onset, including 
environmentally sensitive epigenetics, 
microbiomics (  21  ), metabolic events, 
and specifi  c dietary changes. The new 
eyes of T1D research will likely include 
epigenetic epidemiology (  22  ), serologi-
cal markers of infections and metage-
nomics (  23  ), metabolomics (  24  ), and 
characterization of social ties (  25  ). By 
combining several of these techniques 
and appropriate statistical analyses, it 
may be possible to start characterizing 
the T1D   “  enviromentome.  ”   We sug-
gest that the development of whole-
environment scans  —  data-driven inves-
tigation of a person  ’  s milieu using all 
available information on geographical 
location and personal history  —  will fa-
cilitate this process. Such a data-driven 
strategy will help us discover causal envi-
ronmental factors and will extend classical 
hypothesis-driven epidemiology. 
  To facilitate this shift, medical re-
searchers will have to develop new tools 
to examine an individual  ’  s personal ge-
ography and history and that will enable 
the individual  ’  s environment to be 
mapped. Some of these tools (cohort 
studies, computational mathematics, and 
statistics) will likely be inspired by those 
forged to explore infectious disease 
transmission or social networks (  25  ). 
Epigenetics, microbiome and microbi-
ology, metabolism and alimentation, 
and climatic environmental exposures 
are often interconnected (  26  ). Seeking 
relationships between the geography of 
human and animal movements with 
particularly given that T1D is on the 
rise in very young children, where the 
incidence has doubled in the last 20 yr 
(  17  ). So far, no genetic or environmen-
tal factors have emerged to explain this 
pediatric phenomenon, but the fact that 
autoantibodies appear during the fi  rst 
2 yr of life implicates early events (  5  ). 
Emerging or rapidly evolving environ-
mental changes may be to blame, but 
Ariadne  ’  s clue is missing. 
This sort of metabolomic 
approach to T1D natural 
history may be a pioneering 
example of environmental 
data-driven approaches.
  Another epidemiological enigma is 
the major diff  erence in T1D prevalence 
across countries of the old continent. 
For example, Sardinia and Finland have 
the highest incidence of T1D worldwide 
(    31/100,000 and 36/100,000, respec-
tively), which is 5  –  8 times the incidence 
in other European countries. Both of 
these countries have distinctive genetic, 
cultural, and environmental characteris-
tics, which thus far have defi  ed  the 
imaginations of T1D researchers. 
  Working hypotheses to explain the 
etiology of T1D are few and far be-
tween. One is the   “  hygiene hypothesis  ”   
(  18  ), which suggests that fewer infec-
tions in modern day children results in 
decreased immune defenses and, as a re-
sult, increased incidence of childhood-
onset diseases  —  asthma and T1D in 
particular (  19  ). This may be an attrac-
tive hypothesis, but it has not yet been 
supported by scientifi  c data. And nota-
ble examples of infections used to sup-
port the hygiene hypothesis often 
include prototypical infectious diseases, 
such as rheumatic fever, tuberculosis, 
mumps, measles, and hepatitis A (  19  ). 
However, these diseases tend to occur 
later in life, and thus may not be the 
best refl   ection of pathogen exposure 
during early infancy. Indeed, the im-
mune systems of children today are 
largely trained by frequent viral en-
counters in schools, urban environ-
of 48 g/d in adults.      cells are equipped 
with glutamate receptors and transport-
ers and respond to glutamate with en-
hanced insulin secretion, suggesting a 
role for this metabolite in insulin regu-
lation. However, the small overall mass 
of      cells makes them unlikely to be a 
signifi  cant contributor to increased se-
rum glutamate (  11  ). It is likely that an 
increased glutamate load in      cells in-
creases the activity of GAD65, one of 
the major      cell antigens. Thus, one 
can hypothesize that transiently elevated 
glutamate and increased GAD activity 
might trigger or accelerate      cell dam-
age through cytolytic or autoimmune 
processes. This process might be akin to 
autoimmunity of the thyroid, in which 
a higher iodine supply increases thyro-
peroxidase activity and the incidence of 
autoimmune thyroiditis (  12  ). 
  Glutamate seems to be important to 
the microbiome composition, and some 
researchers speculate that   Escherichia coli   
survive in the gut because of their Gad-
ABC and CadBA glutamate- and lysine-
dependent acid-resistance systems (  13  ). 
Glutamine and glutamate also have direct, 
but still unclear, eff  ects on the immune 
system (  14  ). 
  Increased levels of lysophosphatidyl-
choline (LPC) were detected by Orešic ˇ 
et al. in future T1D children at birth and 
during their fi  rst years (  6  ). These lipid 
changes might result from events starting 
in utero, possibly linked to the mother  ’  s 
nutrition and metabolism. In addition, 
LPC, which is a bioactive byproduct of 
phospholipase A  2   (PLA  2  ) and a constitu-
ent of oxidized low-density lipoprotein, 
can infl  uence the chemotaxis of leuko-
cyte subpopulations during infl  ammation 
(  15  ). And group VIA phospholipase A  2   
(iPLA  2      ) participates in insulin secretion, 
as revealed by pharmacological or genetic 
manipulation of iPLA  2       activity in      cells 
(  16  ). For simplicity, in this article, we 
have restricted this discussion to glutamate 
and LPC variations in pre-T1D children, 
but other components of the metabolome 
might also be important for the genesis of 
the prediabetic state. 
  Epidemiological enigmas 
  The implications of the study by Orešic ˇ 
et al. are potentially important (  6  ), JEM VOL. 205, December 22, 2008  2955
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Even though the difficulties 
are monumental, the time 
may be ripe to encourage 
these approaches because 
they will enable research 
efforts to go from disease 
causes to disease 
mechanisms.
  Future epidemiological investigations 
that attempt to dissect these tricky gene  –
  environment interactions might benefi  t 
from using Mendelian randomization in 
which a functional genetic variant acts as 
a proxy for an environmental exposure 
(  30  ). Currently, establishing causal rela-
tionships between environmental expo-
sures and common diseases is beset with 
problems of unresolved confounding, re-
verse causation and selection bias that 
might result in spurious inferences. Men-
delian randomization provides a means of 
overcoming these problems, because the 
inheritance of genetic variant is indepen-
dent of (i.e., randomized in respect to) the 
inheritance of other traits, according to 
Mendel  ’  s law of independent assortment. 
Regarding the study by Orešic ˇ et al. (  6  ), it 
is conceivable that genetic variants having 
suffi   cient infl  uence on glutamate or lyso-
phosphatidyl choline metabolism may 
help confi  rm the postulated implication 
of these metabolites in T1D. 
  Few researchers have started to 
match genetic diversity with environ-
mental variety.   HLA   variants (which 
have their own geographical distribu-
tion) could infl  uence T1D susceptibility, 
predominantly in specifi  c clustered en-
vironments (  31  ). Regional population 
diff   erences, which presumably include 
lifestyle and geographic and biotic fac-
tors, have been shown to modulate ge-
nome-wide gene expression to the same 
extent as genetic divergence (  32  ). DNA 
changes associated with T1D may not 
lead directly to disease, but instead may 
act on intermediate molecular pheno-
types that in turn induce modifi  cations 
in high-order disease traits. Recently, 
gene-expression genetics (  “  expression 
mapping  ”  ) in human populations has 
patient samples on an epidemiological 
scale. Findings gleaned from laboratory 
mice will not help at this early phase. 
Although many scientifi  c minds object 
to such   “  fi  shing  expeditions,  ”   these 
forays will be the inevitable fi  rst steps 
before hypotheses can be generated 
and tested in patients and experimental 
models. 
  After all, genome-wide association 
analyses of T1D genetics have become 
highly respected fi  shing  expeditions 
across the hundreds of thousands of sin-
gle-nucleotide polymorphisms that are 
now available to tag the individual ge-
nome. It took 20 yr to devise appropri-
ate tools for investigating individual 
genome variability through genotyping 
techniques, genomic statistics, and ge-
netic epidemiology, starting with either 
testing specifi  c candidate genes selected 
by investigators or with low-powered 
microsatellite markers of the whole ge-
nome. We are now close to obtaining a 
full characterization of whole genomic 
and epigenomic variations. Similarly, it 
will take time to benefi  t fully from a sys-
tematic exploration of all available pop-
ulation and hospital databases providing 
historical and/or prospective informa-
tion on the history of infections, drug 
use, and natural or industrial environ-
mental exposures. 
  Genetics limits and new challenges 
  Genetic predisposition provides only a 
limited part of T1D causality, as 50  –
  70% of monozygous twins are not con-
cordant for the disease, and migrant 
children seem to adopt the T1D inci-
dence of the country where they live 
rather than from where they originate. 
Genetics are not expected to contribute 
to the current increase of T1D inci-
dence in young children, in whom 
  HLA   predisposition may even have di-
minished (  29  ). Pure genetic analysis 
currently disregards the complexities of 
gene  –  environment interactions. How-
ever, genetic predisposition is only in-
dicated at two levels: interaction with 
a hypothesized environmental factor 
(where, for example, the phenotype to 
be tested is a viral infection, not T1D) 
or development of T1D after interac-
tion with the virus. 
trajectories of infectious diseases, for ex-
ample, will shed light on events at the 
population level. An eventual readout of 
an individual  ’  s predisposition to T1D 
should be derived from a combination 
of genetic and environmental factors. 
Indeed, certain epigenetic marks are de-
pendent on specifi  c  food  components 
(  27  ), xenobiotics, pollutants, and metals. 
Such analyses will undoubtedly uncover 
unexpected and intriguing associations. 
For example, cold-chain development 
paralleled the Crohn  ’  s disease outbreak 
of the 20th century (  28  ). The observa-
tion that old refrigerators are a major 
risk factor for disease may seem bizarre 
until one considers that bacteria identi-
fi  ed in Crohn  ’  s disease were found to 
live at low temperatures. 
  Epigenetics, microbiome and mi-
crobiology, metabolism and nutrient in-
take, and climatic and environmental 
exposures are all dynamic. Each under-
goes rapid adaptive changes during 
infancy and early childhood, thus con-
tributing to plasticity at the organism 
level, including the developing immune 
system. If these time-dependent changes 
are stochastic, fi  nding causative needles-
in-the-haystack will be a great challenge. 
If the stochastic nature depends mostly 
on somatic and tissue-specifi  c forces im-
pinging on gene exp  ression and protein 
activity, the task will be formidable. 
By combining several of 
these techniques and 
appropriate statistical 
analyses, it may be possible 
to start characterizing the 
T1D “enviromentosome.”
  Studies might thus have to be lon-
gitudinal to enable the observation 
of relevant time-dependent changes. 
  “  Hit-and-run  ”   encounters with envi-
ronmental agents will not always leave 
detectable traces. Adequate control 
populations will have to be defi  ned for 
each of the approaches. Another chal-
lenge is that all approaches will initially 
have to be blind (rather than   “  hypoth-
esis-driven  ”  ), and thus will require 2956  TYPE 1 DIABETES ENVIROMENTOME   | Bougn  è  res and Valleron 
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started to provide a more objective view 
of the contribution of genetic variation 
to variations in gene expression  — 
thousands of traits have been found to be 
under the control of well-defi  ned  ge-
netic loci. The genetics of gene expres-
sion have been studied in human 
lymphoblastoid cell lines and human 
liver, where T1D-associated single-
nucleotide polymorphisms in genome-
wide scans have also been associated with 
liver gene-expression traits (  33  ). Not 
only will this approach enable us to un-
derstand the biology underlying the sta-
tistical association of a genomic variant 
with a complex disease, it will ultimately 
help determine which parts of the gene-
expression variation are attributable to 
genetic or nongenetic factors. The same 
kind of gene-expression studies can be 
undertaken to test the eff  ect of environ-
mental exposures in relevant populations. 
However, the problem persists of the tis-
sue where gene expression is expected to 
be relevant to the disease, such as in lym-
phocytes for asthma or T1D (  34  ). 
  The challenges of new lands 
  Metabolomics, metagenomics, mi-
crobiology, epigenetic epidemiology, 
and gene-expression studies will face 
the same high-throughput challenges 
that whole-genome strategies did. The 
utilization of accurate techniques for 
characterizing individual markers, ap-
propriate case-control comparisons, the 
sophistication of computational mathe-
matics, and the precautions required to 
accurately interpret the data will be re-
quired to overcome the blindness of the 
experimental design and the complex-
ity and heterogeneity of T1D causality. 
Even though the diffi   culties are mon-
umental, the time may be ripe to en-
courage these approaches because they 
will enable research eff  orts to go from 
disease causes to disease mechanisms. 
This strategy should off  set the reliance 
on animal models, not only because of 
their own limitations but also because 
these models drive ideas and studies in 
only one direction: from disease mech-
anisms to causes. Incentives to use large 
fi  shing expeditions in man will be high 
because, in addition to contributing to 
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